Business briefs: Amgen and Omnicom Group
Amgen released an outline of their long-term strategy last Thursday, with a focus on how they will continue to spread out their efforts on two different commercial models: biologics and biosimilars. "The company is clearly straddling two business opportunities that sometimes seem in conflict with each other -- a defender of the innovative products and a participant in biosimilar products. That tension is going to continue to be difficult for them to manage," said Sanford Bernstein analyst Geoffrey Porges. The Thousand Oaks-based drug manufacturer reported plans to launch six new biosimilars beginning in 2017. Amgen also expects to deliver over $1 billion in new sales from new and emerging markets. The company plans to launch its first product in Chinese markets by 2015, and Japanese markets by 2016. In-market products, Prolia and XGEVA, saw a combined $1.2 billion in sales for 2012, which they expect to exceed $3 billion in revenue. Enbrel was cited as their leading and most valuable biologic.
Omnicom Group reported a decline of 1.3% in their Pharma and Healthcare business for 2012. The group as a whole saw an increase in revenue by 2.5% with domestic revenue increasing by 4.5% and international revenue increasing by .5%, year-over-year.